1. Home
  2. IKT vs NAKA Comparison

IKT vs NAKA Comparison

Compare IKT & NAKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IKT
  • NAKA
  • Stock Information
  • Founded
  • IKT 2008
  • NAKA 2019
  • Country
  • IKT United States
  • NAKA United States
  • Employees
  • IKT N/A
  • NAKA N/A
  • Industry
  • IKT Biotechnology: Pharmaceutical Preparations
  • NAKA
  • Sector
  • IKT Health Care
  • NAKA
  • Exchange
  • IKT Nasdaq
  • NAKA Nasdaq
  • Market Cap
  • IKT 131.6M
  • NAKA 126.6M
  • IPO Year
  • IKT 2020
  • NAKA 2024
  • Fundamental
  • Price
  • IKT $1.66
  • NAKA $14.22
  • Analyst Decision
  • IKT Buy
  • NAKA
  • Analyst Count
  • IKT 2
  • NAKA 0
  • Target Price
  • IKT $8.00
  • NAKA N/A
  • AVG Volume (30 Days)
  • IKT 126.7K
  • NAKA 1.7M
  • Earning Date
  • IKT 08-13-2025
  • NAKA 08-13-2025
  • Dividend Yield
  • IKT N/A
  • NAKA N/A
  • EPS Growth
  • IKT N/A
  • NAKA N/A
  • EPS
  • IKT N/A
  • NAKA N/A
  • Revenue
  • IKT N/A
  • NAKA $2,470,466.00
  • Revenue This Year
  • IKT N/A
  • NAKA N/A
  • Revenue Next Year
  • IKT N/A
  • NAKA N/A
  • P/E Ratio
  • IKT N/A
  • NAKA N/A
  • Revenue Growth
  • IKT N/A
  • NAKA N/A
  • 52 Week Low
  • IKT $1.12
  • NAKA $0.65
  • 52 Week High
  • IKT $4.20
  • NAKA $34.77
  • Technical
  • Relative Strength Index (RSI)
  • IKT 35.43
  • NAKA N/A
  • Support Level
  • IKT $1.91
  • NAKA N/A
  • Resistance Level
  • IKT $2.07
  • NAKA N/A
  • Average True Range (ATR)
  • IKT 0.11
  • NAKA 0.00
  • MACD
  • IKT -0.03
  • NAKA 0.00
  • Stochastic Oscillator
  • IKT 0.00
  • NAKA 0.00

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

About NAKA Kindly MD Inc. Common Stock

Kindly MD Inc is a holistically focused pain management clinic and healthcare data company. It offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Its specialty outpatient clinical services are offered on a subscription and fee-for-service basis to augment traditional healthcare. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy.

Share on Social Networks: